Methods of using potassium channel inhibiting compounds

Abstract

The present invention relates to the use of an effective amount of at least one potassium KvI.3 channel inhibitor or of an effective amount of at least one compound having in addition to its potassium KvI.3 channel inhibiting properties also CBx modulating properties and / or potassium K(atp) channel opening properties for the manufacture of a medicament for the prophylaxis, treatment, delayed progression, delayed onset and / or inhibition of various medical conditions in subjects in need thereof . The diseases are obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity , asthma, glucose metabolism - in particular, insulin resistance, hyperglycaem ea and / or glucose intolerance - neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripher al vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration , pain - including neuropathic pain and chronic pain - and impotence. The compounds are a.o. 4, 5-dihydropyrazole derivatives, imidazole derivatives, diazoxide, NN414, R(+) -WIN55212-2, HU-308, Rimonaband, SR-147778.

Description

Invention field [0001] The present invention involves administering an effective amount of at least one potassium K to a subject in need v1.3 Channel inhibitors are methods of treating, preventing or inhibiting a variety of medical conditions, such as type I and type II diabetes. Optionally, potassium K v1.3 Channel inhibitor not only has its potassium K v1.3 Channel inhibitory property, also has CB x Regulatory properties and / or potassium K (atp) The channel is open in nature. Background of the invention [0002] Insulin is a key regulator of glucose and liposome homeostasis and cell proliferation. It is secreted into the bloodstream by pancreatic β-cells that respond to increases in serum glucose and amino acids, for example, after a meal, but also as part of the cephalic phase before the absorption of a meal. This insulin binds to specific insulin receptors (IR) at the plasma membrane of insulin-responsive tissues such as skeletal muscle, fat, and liver. It is believed that IR...

AI Technical Summary

Problems solved by technology

In addition, potassium K v1.3 Inhibition of increases peripheral insulin sensitivity

Images